Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU].
Gomollón F, García-López S, Sicilia B, Gisbert JP, Hinojosa J; en representació del Grupo Espa˜nol de Trabajode Enfermedad de Crohn y Colitis Ulcerosa or Spanish Group for Working on Crohn’sDisease and Ulcerative Colitis (GETECCU). Gomollón F, et al. Gastroenterol Hepatol. 2013 Oct;36(8):e1-47. doi: 10.1016/j.gastrohep.2012.11.001. Gastroenterol Hepatol. 2013. PMID: 24215088 Spanish. No abstract available.
Accuracy of advanced endoscopy and fecal calprotectin for prediction of relapse in ulcerative colitis: a prospective study.
Jauregui-Amezaga A, López-Cerón M, Aceituno M, Jimeno M, Rodríguez de Miguel C, Pinó-Donnay S, Zabalza M, Sans M, Ricart E, Ordás I, González-Suárez B, Cuatrecasas M, Llach J, Panés J, Pellise M. Jauregui-Amezaga A, et al. Among authors: aceituno m. Inflamm Bowel Dis. 2014 Jul;20(7):1187-93. doi: 10.1097/MIB.0000000000000069. Inflamm Bowel Dis. 2014. PMID: 24874457
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.
Iborra M, Pérez-Gisbert J, Bosca-Watts MM, López-García A, García-Sánchez V, López-Sanromán A, Hinojosa E, Márquez L, García-López S, Chaparro M, Aceituno M, Calafat M, Guardiola J, Belloc B, Ber Y, Bujanda L, Beltrán B, Rodríguez-Gutiérrez C, Barrio J, Cabriada JL, Rivero M, Camargo R, van Domselaar M, Villoria A, Schuterman HS, Hervás D, Nos P; Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU).. Iborra M, et al. Among authors: aceituno m. J Gastroenterol. 2017 Jul;52(7):788-799. doi: 10.1007/s00535-016-1274-1. Epub 2016 Oct 8. J Gastroenterol. 2017. PMID: 27722996
Erratum to: Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.
Iborra M, Gisbert JP, Bosca-Watts MM, López-García A, García-Sánchez V, López-Sanromán A, Hinojosa E, Márquez L, García-López S, Chaparro M, Aceituno M, Calafat M, Guardiola J, Belloc B, Ber Y, Bujanda L, Beltrán B, Rodríguez-Gutiérrez C, Barrio J, Cabriada JL, Rivero M, Camargo R, van Domselaar M, Villoria A, Schuterman HS, Hervás D, Nos P; Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU).. Iborra M, et al. Among authors: aceituno m. J Gastroenterol. 2017 Jul;52(7):875-877. doi: 10.1007/s00535-016-1293-y. J Gastroenterol. 2017. PMID: 27885420 Free article. No abstract available.
42 results